Dr. Reddy's Lab wins right to sell Gilead’s Remdesivir in 127 countries including India

  • Posted on: 15 June 2020
  • By: admin

Dr. Reddy's Laboratories has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Johnson & Johnson to begin Phase 1/2a Clinical Trials of COVID-19 vaccine in July

  • Posted on: 12 June 2020
  • By: PharmaTutor News

Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the trial is now expected to commence in the second half of July.


Swarupananda Mukherjee*, Sohini Bera, Moumoyee Chakraborty 
NSHM Knowledge Campus, Kolkata – Group of Institutions,
Department of Pharmaceutical Technology, 124, B L Saha Road,
Kolkata, India


Corona viruses are a family of enveloped, positive stranded, single stranded RNA viruses. This corona virus family consists of pathogens of several human and animal species including SARS-CoV, NovelCOVID-19 but now referred to as SARS-CoV-2 by the Study Group. SARS-CoV-2 International Committee on Virus Taxonomy Corona Virus belongs to the genus Beta corona virus family Corona viridae. The virus has spread globally since its introduction, causing millions of deaths and critically affecting our health services and economies. There are currently no approved preventive drugs or treatment methods available. Hundreds of clinical trials were performed to find treatments that were successful. Here we are reviewing currently reported clinical studies for COVID-19 treatment and prevention to give an overview and perspective into the global response.

Messe Frankfurt to focus on highlighting strong anti-counterfeiting measures in wake of Covid-19

  • Posted on: 6 June 2020
  • By: PharmaTutor News

As demand for medical supplies soars worldwide in the fight against Covid-19, there is a parallel risk of substandard and counterfeit medicines in the global market. With India being one of the world's largest producers of medical supplies, there is an urgent need to bring in strong anti-counterfeiting measures which will be addressed at Messe Frankfurt’s upcoming conference - Pharmasafe India 2020. 

Corona virus disease-2019 (COVID-19) : The epidemic and the challenges

Disha Chouhana*1, Dr. Rajesh Mujariya2
1*Department of Pharmaceutical Chemistry, School of Pharmaceutical Science and Research , Balaghat, Madhya Pradesh, India
2Department of Pharmaceutics,  School of Pharmaceutical Science and Research , Balaghat, Madhya Pradesh, India

There is a new public health crises threatening the world with the emergence and spread of 2019 novel corona virus (2019-nCoV) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of corona virus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d.

Five tips on how to live with novel coronavirus

After seventy days of lockdown, the unlock 1.0 is put into action. Officially designated lockdown 5.0, from June 1, 2020, the economy and ordinary life are returning to normalcy in a controlled and phased manner. This is the beginning of a new normal. It is going to be a long haul. Experts and officials are suggesting that ‘we must learn to live with the virus’. With vaccine still months away, we need to live in a new normal. Speaking to India Science Wire, Prof. K Vijay Raghavan, Principal Scientific Advisor to the Government of India, gave five tips to ‘living with the virus’.

Novavax Selects AGC Biologics to Manufacture Matrix-M™ Adjuvant for Novel COVID-19 Vaccine

  • Posted on: 4 June 2020
  • By: PharmaTutor News

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax’ coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

  • Posted on: 1 June 2020
  • By: PharmaTutor News

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies announced a clinical strategy to treat patients with moderate to severe COVID-19 who require hospitalization. ATR-002, an oral small molecule, has been proven in preclinical trials to block viral propagation of SARS-CoV-2 and to have an immunomodulatory effect leading to a decreased cytokine and chemokine release. This dual benefit makes the MEK-inhibitor ATR-002 particularly relevant for the treatment of COVID-19.

Asymptomatic COVID-19 positive individuals don't have potential to infect others: Health DG Malaysia

  • Posted on: 31 May 2020
  • By: PharmaTutor News

COVID-19 positive individuals who are asymptomatic do not have the potential to infect others because they have a low “virus load” compared to those who are symptomatic, said Health director-general Datuk Dr Noor Hisham Abdullah reported by Bernama.